A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia

Affiliations

• ¹ Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
• ² Department of Hematology, Henan Cancer Hospital, Zhengzhou, China.
• ³ Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
• ⁴ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
• ⁵ Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
• ⁶ Department of Hematology, Hainan General Hospital, Haikou, China.
• ⁷ Department of Hematology, Yichang Central People's Hospital, Yichang, China.
• ⁸ Department of Hematology, Wuxi People's Hospital, Wuxi, China.
• ⁹ Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
• ¹⁰ Department of Medical Research, InnoCare Pharma Limited, Beijing, China.
• ¹¹ Department of Biostatistics, InnoCare Pharma Limited, Beijing, China.